UB Paderborn / Katalog / Suche / in CDI

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors

Oncology reports, 2022-02, Vol.47 (2)

2022

Volltextzugriff (PDF)

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L[1.sup.low] and immune desert-like mouse tumors

Oncology reports, 2022-02, Vol.47 (2), p.1

2022

Volltextzugriff (PDF)

Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1 low and immune desert‑like mouse tumors

Oncology reports, 2021-12, Vol.47 (2), Article 36

2021

Volltextzugriff (PDF)

Abstract B046: Addition of anti-VEGF overcomes the anti-PD-L1 refractoriness in a OV2944-HM-1 tumor model

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.B046-B046

2019

Volltextzugriff (PDF)

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11): 1555-1561 (2008)]

Chemical and Pharmaceutical Bulletin, 2009/10/01, Vol.57(10), pp.1178-1178

2009

Volltextzugriff (PDF)

Porous silicon based extended-bandwidth rugate filters for mid-infrared application

Infrared physics & technology, 2010-07, Vol.53 (4), p.292-294

2010

Volltextzugriff (PDF)

Broadband rugate filters based on porous silicon

Optical materials, 2008-09, Vol.31 (1), p.102-105

2008

Volltextzugriff (PDF)

Biological Properties of Androgen Receptor Pure Antagonist forTreatment of Castration-Resistant Prostate Cancer: Optimization From Lead Compound to CH5137291

The Prostate, 2011, Vol.71 (12), p.1344-1356

2011

Volltextzugriff (PDF)

Discovery of 7α-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure–activity relationships

Bioorganic & medicinal chemistry, 2007, Vol.15 (1), p.174-185

2007

Volltextzugriff (PDF)

Abstract A220: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for treatment of castration-resistant prostate cancer

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A220-A220

2009

Volltextzugriff (PDF)

Abstract A219: Universal efficacy of novel androgen receptor pure antagonist, CH5137291, against broad spectrum prostate cancer including castration-resistant prostate cancers

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A219-A219

2009

Volltextzugriff (PDF)

Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB Knockout

Cancer diagnosis & prognosis, 2022-09, Vol.2 (5), p.533-541

2022

Volltextzugriff (PDF)

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure-Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11)

Chemical & pharmaceutical bulletin, 2009-10, Vol.57 (10)

2009

Volltextzugriff (PDF)

アフラトキシンB1誘導ラット肝癌細胞で見られる14-3-3βの発現亢進とその役割

Maikotokishin, 2000, Vol.50 (2), p.83-91

2000

Volltextzugriff (PDF)

Regulation of RNG105/caprin1 dynamics by pathogenic cytoplasmic FUS and TDP-43 in neuronal RNA granules modulates synaptic loss

Heliyon, 2023-06, Vol.9 (6), p.e17065-e17065, Article e17065

2023

Volltextzugriff (PDF)

Abstract 1: The Very Core Limit Of Endovascular Therapy For Acute Stroke With A Large Ischemic Region

Stroke (1970), 2023-02, Vol.54 (Suppl_1)

2023

Volltextzugriff (PDF)

Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections

Infection and drug resistance, 2018-01, Vol.11, p.1073-1081

2018

Volltextzugriff (PDF)

Association of Time Course of Thrombectomy and Outcomes for Large Acute Ischemic Region: RESCUE–Japan LIMIT Subanalysis

Stroke: vascular and interventional neurology, 2023-09, Vol.3 (5)

2023

Volltextzugriff (PDF)

Mode of Imaging Study and Endovascular Therapy for a Large Ischemic Core: Insights From the RESCUE-Japan LIMIT

Journal of stroke, 2023-09, Vol.25 (3), p.388-398

2023

Volltextzugriff (PDF)

Randomized Clinical Trial of Endovascular Therapy for Acute Large Vessel occlusion with Large Ischemic Core (RESCUE-Japan LIMIT) : Rationale and Study Protocol

Neurologia medico-chirurgica, 2022-08, Vol.62 (suppl-2), p.156-164

2022

Volltextzugriff (PDF)

Randomized Clinical Trial of Endovascular Therapy for Acute Large Vessel occlusion with Large Ischemic Core (RESCUE-Japan LIMIT) : Rationale and Study Protocol

Neurologia medico-chirurgica, 2022-03, Vol.62 (3), p.156-164

2022

Volltextzugriff (PDF)

Randomized Clinical Trial of Endovascular Therapy for Acute Large Vessel Occlusion with Large Ischemic Core (RESCUE-Japan LIMIT): Rationale and Study Protocol

Neurologia medico-chirurgica, 2021, pp.rc.2021-0311

2021

Volltextzugriff (PDF)

Mode of Imaging Study and Endovascular Therapy for a Large Ischemic Core: Insights From the RESCUE-Japan LIMIT

Journal of stroke, 2023-09, p.388-398

2023

Volltextzugriff (PDF)

Long-term results of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer

Annals of oncology, 2015-11, Vol.26, p.vii98

2015

Volltextzugriff (PDF)

Free-energy analysis of lysozyme–triNAG binding modes with all-atom molecular dynamics simulation combined with the solution theory in the energy representation

Chemical physics letters, 2013-02, Vol.559, p.94-98

2013

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L[1.sup.low] and immune desert-like mouse tumors

Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1 low and immune desert‑like mouse tumors

Abstract B046: Addition of anti-VEGF overcomes the anti-PD-L1 refractoriness in a OV2944-HM-1 tumor model

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11): 1555-1561 (2008)]

Porous silicon based extended-bandwidth rugate filters for mid-infrared application

Broadband rugate filters based on porous silicon

Biological Properties of Androgen Receptor Pure Antagonist forTreatment of Castration-Resistant Prostate Cancer: Optimization From Lead Compound to CH5137291

Discovery of 7α-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure–activity relationships

Abstract A220: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for treatment of castration-resistant prostate cancer

Abstract A219: Universal efficacy of novel androgen receptor pure antagonist, CH5137291, against broad spectrum prostate cancer including castration-resistant prostate cancers

Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB Knockout

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure-Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11)

アフラトキシンB1誘導ラット肝癌細胞で見られる14-3-3βの発現亢進とその役割

Regulation of RNG105/caprin1 dynamics by pathogenic cytoplasmic FUS and TDP-43 in neuronal RNA granules modulates synaptic loss

Abstract 1: The Very Core Limit Of Endovascular Therapy For Acute Stroke With A Large Ischemic Region

Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections

Association of Time Course of Thrombectomy and Outcomes for Large Acute Ischemic Region: RESCUE–Japan LIMIT Subanalysis

Mode of Imaging Study and Endovascular Therapy for a Large Ischemic Core: Insights From the RESCUE-Japan LIMIT

Randomized Clinical Trial of Endovascular Therapy for Acute Large Vessel occlusion with Large Ischemic Core (RESCUE-Japan LIMIT) : Rationale and Study Protocol

Randomized Clinical Trial of Endovascular Therapy for Acute Large Vessel occlusion with Large Ischemic Core (RESCUE-Japan LIMIT) : Rationale and Study Protocol

Randomized Clinical Trial of Endovascular Therapy for Acute Large Vessel Occlusion with Large Ischemic Core (RESCUE-Japan LIMIT): Rationale and Study Protocol

Mode of Imaging Study and Endovascular Therapy for a Large Ischemic Core: Insights From the RESCUE-Japan LIMIT

Long-term results of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer

Free-energy analysis of lysozyme–triNAG binding modes with all-atom molecular dynamics simulation combined with the solution theory in the energy representation

Aktive Filter

Suchergebnisse filtern